AKT1 and esophageal squamous cell carcinoma: We verified the practicality of this system by studying the changes in a molecular pathway utilizing an AKT (protein kinase B) shRNA knockdown approach in ESCC cell lines to knockdown AKT, which is frequently deregulated in cancers, to confirm its functionality in this in vivo animal model system.